Hydromorphone Extended-Release Tablets Approved

3/4/2010
The FDA has approved CombinatoRx’s Exalgo (hydromorphone hydrochloride) extended-release tablets for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Clin-eguide™ is an online clinical decision support tool that provides the most accurate evidence-based information for health care providers in the clinical setting. It integrates trusted content from Ovid, Facts & Comparisons®, and Lippincott Williams and Wilkins, as well as other premier publishers.